OS by age for patients with unfavorable risk cytogenetics. Patients younger than 56 years (n = 108) had a median survival of 11 months, patients aged 56 to 65 years (n = 70) had a median survival of 5 months, and patients aged 66 to 75 years (n = 78) had a median survival of 4 months, as did the 27 patients older than 75 years.